Unravel the double helix of 23andMe's rollercoaster journey from Silicon Valley darling to Wall Street wallflower. This episode decodes the DNA of a company that turned saliva into gold... and then watched it evaporate faster than you can say "genome sequencing." 🧪 From $1000 kits to $99 spit tubes: How 23andMe made genetics go viral 🔬 The FDA showdown: When regulators crashed the DNA party 💊 Pivot or perish: 23andMe's adventurous leap into drug discovery 💸 SPACs, hacks, and setbacks: The turbulent path to going public 🩺 Telehealth dreams and Ozempic schemes: 23andMe's desperate bid for relevance Join us as we swab the inner cheek of 23andMe's business strategy, examining how a revolutionary idea morphed into a cautionary tale of overreach and identity crisis. We'll dissect the company's attempts to monetize your genetic code and ponder if there's still life in those test tubes. Is 23andMe's future written in the stars (or rather, in its customers' DNA)? Or will it need more than a genetic miracle to survive? Tune in for a wickedly entertaining analysis that's more twisted than a double helix !#23andMe #GeneticTesting #StartupStruggles #BusinessStrategy #DNADrama #TechFails #SPACAttack 📕Show Menu - https://bit.ly/bcpshowmenu The Big Con Podcast: Emily and Dale are bringing you in on the Con. Strategy doesn't have to be something only those who master PowerPoint can do; we're making it approachable to everyone! The Big Con podcast is dedicated to demystifying and simplifying the world of strategy, exploring the businesses and individuals who've either harnessed it for success or missed the mark.  Subscribe and follow today to get all new episodes in your feed immediately.